



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Proficiency testing for veterinary laboratories

Histopathology and immunohistochemistry interpretation (PT II 25)

Distribution date: December 2025

General comments

The TSE interpretation EQA is an exercise that allows all the NRLs to demonstrate their competence at reading stained/immunolabelled slides as part of their TSE diagnostic capability.

Attached below you will find a table summarising the results of the 2024 EQA round in conjunction with each participant ID.

The use of inconclusive/unsuitable for a case in which a definitive diagnosis is considered possible is not an 'incorrect' result in this context. A negative case called positive, or a positive case interpreted as negative are the only results which are considered 'incorrect'.

Correct and 'Safe' results are highlighted **green**. 'Incorrect' results are highlighted in **red**. Inconclusive or unsuitable returns are highlighted in **yellow**.

In the scrapie IHC category, readers were also invited to comment on whether the case is classical or atypical. Where a case is correctly diagnosed as positive, but subsequently misclassified, this has been identified on the table by highlighting the fonts of either "Pos-A" or "Pos-C" in **pink**.

You should each have received email notification of your unique 'ObserverID'. You will need this to identify your results in the table. Please keep this information safely – your ID will NOT change with subsequent rounds. If you have misplaced your ID then please contact Dr Giuseppe Ru (giuseppe.ru@izspltv.it) directly, and the information will be re-sent. If you know of new staff who require to be added to the programme, or existing members of staff who no longer need to participate in this EQA then please contact us.

It is important to review any cases for which you have given an incorrect answer (highlighted in **red and **pink**) and fill the 'Slide review form' (at the end of this document) and return it to Giuseppe Ru (giuseppe.ru@izspltv.it) and a copy to Barbara Iulini (barbara.iulini@izspltv.it).**

Please use one form for each misclassified case.

This confirms for the EURL (and your own third party quality systems) that appropriate follow-on review of sections has taken place with those readers who require to re-read particular slides.



TSE EURL

Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Comments on the results

The summary table below has grouped the cases according to species so if you wish to refer back to a particular case, please check the case number carefully at the top of the table.

Thank you.

Date: 18/2/26

Barbara Iulini.....
*Referent for Confirmatory Histopathology and Immunohistochemistry tests
Veterinary pathologist of Neuropathology Laboratory at IZSPLVA Italy*

Giuseppe Ru.....
Director of TSE EURL

Table 1. Results submitted by the participants in the I125 PT

Case number	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Species	EE	IHC	IHC	IHC	IHC	IHC	IHC	EE	IHC	IHC	EE	IHC	EE	IHC	IHC
Gold standard result	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
Test Type	Ov	Ov	Ov	Ov	Ov	Ov	Ov	Bov	Bov	Ov	Bov	Ov	Ov	Ov	Bov
IHC result of all H&E sections															
User ID															
084	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
126	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Inc	Pos-A	Pos	Pos-C	Inc
140	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
162	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Inc
168	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
172	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-C	Pos	Pos-C	Neg
184	Uns	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
227	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
261	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
288	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
298	Inc	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Uns	Neg	Pos-A	Pos	Pos-C	Inc
307	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Pos
340	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
346	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
364	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Inc
386	Pos	Pos-C	Pos-C	Uns	Pos-C	Pos-A	Pos-C	Pos	Pos	Uns	Neg	Pos-A	Pos	Pos-C	Neg
393	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
403	Pos	Pos-C	Pos-C	Inc	Pos-C	Pos-A	Pos-C	Pos	Pos	Inc	Neg	Pos-A	Pos	Pos-C	Neg
494	Inc	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Uns	Neg	Pos-A	Pos	Pos-C	Inc
499	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
530	Inc	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
546	Inc	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Uns	Neg	Pos-A	Pos	Pos-C	Neg
574	Inc	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Uns	Neg	Pos-A	Pos	Pos-C	Neg
627	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
668	Neg	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
683	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Pos
685	Inc	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
691	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
710	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
725	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
729	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Inc
743	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
745	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-C	Pos	Pos-C	Neg
775	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
782	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
924	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
934	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
938	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
941	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-C	Neg
962	Pos	Pos-C	Pos-C	Neg	Pos-C	Pos-A	Pos-C	Pos	Pos	Neg	Neg	Pos-A	Pos	Pos-A	Neg



TSE EURL
Istituto Zooprofilattico Sperimentale del
Piemonte, Liguria e Valle d'Aosta – Torino

Istituto Superiore di Sanità – Roma

Histopathology and immunohistochemistry interpretation EQA 2025
Distribution December 2025

Slide review form

Observer ID:	
Date of EQA round:	
Case number:	
Original observer result:	
Intended (gold standard) result:	
Date of review:	
Further observer comments following review:	